These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23908122)

  • 1. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
    Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
    Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
    Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
    BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
    Jensen LR; Garzon B; Heldahl MG; Bathen TF; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2011 Nov; 34(5):1099-109. PubMed ID: 22002757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
    Kim J; Kim E; Euceda LR; Meyer DE; Langseth K; Bathen TF; Moestue SA; Huuse EM
    J Magn Reson Imaging; 2018 Jun; 47(6):1589-1600. PubMed ID: 29205621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
    Huuse EM; Moestue SA; Lindholm EM; Bathen TF; Nalwoga H; Krüger K; Bofin A; Maelandsmo GM; Akslen LA; Engebraaten O; Gribbestad IS
    J Magn Reson Imaging; 2012 May; 35(5):1098-107. PubMed ID: 22170753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
    Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
    PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
    Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
    AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved performance in differentiating benign from malignant sinonasal tumors using diffusion-weighted combined with dynamic contrast-enhanced magnetic resonance imaging.
    Wang XY; Yan F; Hao H; Wu JX; Chen QH; Xian JF
    Chin Med J (Engl); 2015 Mar; 128(5):586-92. PubMed ID: 25698188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
    Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
    NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.